Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
出版年份 2011 全文链接
标题
Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
作者
关键词
-
出版物
Obesity Reviews
Volume 12, Issue 8, Pages 593-601
出版商
Wiley
发表日期
2011-03-15
DOI
10.1111/j.1467-789x.2011.00860.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells
- (2010) Joan M. McKiney et al. BIOLOGICAL CHEMISTRY
- PYY3-36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
- (2010) B. C. T. Field et al. DIABETES
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability andin VivoPotency
- (2010) Elena Sebokova et al. ENDOCRINOLOGY
- Liraglutide for weight loss in obese people
- (2010) Pär Hallberg et al. LANCET
- Liraglutide for weight loss in obese people
- (2010) Thomas Thum et al. LANCET
- Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
- (2009) C. Dirksen et al. DIABETES CARE
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat
- (2009) v. bucinskaite et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
- (2008) David C. Klonoff et al. CURRENT MEDICAL RESEARCH AND OPINION
- Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor-Dependent Control of Glucose Homeostasis
- (2008) K. M. Picha et al. DIABETES
- Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake
- (2008) D. A. Sandoval et al. DIABETES
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
- (2008) Elisabeth B. Rüttimann et al. ENDOCRINOLOGY
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
- An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis
- (2008) Laurie L. Baggio et al. GASTROENTEROLOGY
- Global burden of obesity in 2005 and projections to 2030
- (2008) T Kelly et al. INTERNATIONAL JOURNAL OF OBESITY
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome
- (2008) Karen Elkind-Hirsch et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
- (2008) D RUSSELLJONES MOLECULAR AND CELLULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now